395 related articles for article (PubMed ID: 30354193)
1. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines.
Franco EJ; Rodriquez JL; Pomeroy JJ; Hanrahan KC; Brown AN
Antivir Chem Chemother; 2018; 26():2040206618807580. PubMed ID: 30354193
[TBL] [Abstract][Full Text] [Related]
2. Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.
Pires de Mello CP; Tao X; Kim TH; Bulitta JB; Rodriquez JL; Pomeroy JJ; Brown AN
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109164
[TBL] [Abstract][Full Text] [Related]
3. Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.
Gallegos KM; Drusano GL; D Argenio DZ; Brown AN
J Infect Dis; 2016 Oct; 214(8):1192-7. PubMed ID: 27496974
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
[TBL] [Abstract][Full Text] [Related]
5. Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines.
Franco EJ; Tao X; Hanrahan KC; Zhou J; Bulitta JB; Brown AN
Microorganisms; 2021 Feb; 9(2):. PubMed ID: 33540830
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).
Pires de Mello CP; Drusano GL; Rodriquez JL; Kaushik A; Brown AN
Viruses; 2018 Jun; 10(6):. PubMed ID: 29890736
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus.
Franco EJ; Pires de Mello CP; Brown AN
Viruses; 2021 Apr; 13(5):. PubMed ID: 33925551
[TBL] [Abstract][Full Text] [Related]
8. Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo.
Rothan HA; Bahrani H; Abdulrahman AY; Mohamed Z; Teoh TC; Othman S; Rashid NN; Rahman NA; Yusof R
Antiviral Res; 2016 Mar; 127():50-6. PubMed ID: 26794398
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the potential of baicalin as an antiviral agent for Chikungunya virus infection.
Oo A; Rausalu K; Merits A; Higgs S; Vanlandingham D; Bakar SA; Zandi K
Antiviral Res; 2018 Feb; 150():101-111. PubMed ID: 29269135
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity of stearylamine against chikungunya virus.
Jeengar MK; Kurakula M; Patil P; More A; Sistla R; Parashar D
Chem Phys Lipids; 2021 Mar; 235():105049. PubMed ID: 33422549
[TBL] [Abstract][Full Text] [Related]
11. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
Abdelnabi R; Morais ATS; Leyssen P; Imbert I; Beaucourt S; Blanc H; Froeyen M; Vignuzzi M; Canard B; Neyts J; Delang L
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381577
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of nobiletin against chikungunya virus in vitro.
Lin SC; Chen MC; Li S; Lin CC; Wang TT
Antivir Ther; 2017; 22(8):689-697. PubMed ID: 28406093
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of a peptide-fusion protein (Latarcin-PAP1-Thanatin) against chikungunya virus.
Rothan HA; Bahrani H; Shankar EM; Rahman NA; Yusof R
Antiviral Res; 2014 Aug; 108():173-80. PubMed ID: 24929084
[TBL] [Abstract][Full Text] [Related]
14. A combination of doxycycline and ribavirin alleviated chikungunya infection.
Rothan HA; Bahrani H; Mohamed Z; Teoh TC; Shankar EM; Rahman NA; Yusof R
PLoS One; 2015; 10(5):e0126360. PubMed ID: 25970853
[TBL] [Abstract][Full Text] [Related]
15. Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model.
Pires de Mello CP; Tao X; Kim TH; Vicchiarelli M; Bulitta JB; Kaushik A; Brown AN
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967017
[TBL] [Abstract][Full Text] [Related]
16. Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors.
Baba M; Toyama M; Sakakibara N; Okamoto M; Arima N; Saijo M
Antivir Chem Chemother; 2017 Dec; 25(3):83-89. PubMed ID: 29096526
[TBL] [Abstract][Full Text] [Related]
17. Development of a Real-Time Cell Analysing (RTCA) method as a fast and accurate screen for the selection of chikungunya virus replication inhibitors.
Marlina S; Shu MH; AbuBakar S; Zandi K
Parasit Vectors; 2015 Nov; 8():579. PubMed ID: 26553263
[TBL] [Abstract][Full Text] [Related]
18. Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by
Delang L; Yen PS; Vallet T; Vazeille M; Vignuzzi M; Failloux AB
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135220
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Peptidomimetics as Irreversible CHIKV NsP2 Protease Inhibitors Using Quantum Mechanical-Based Ligand Descriptors.
El-labbad EM; Ismail MA; Abou Ei Ella DA; Ahmed M; Wang F; Barakat KH; Abouzid KA
Chem Biol Drug Des; 2015 Dec; 86(6):1518-27. PubMed ID: 26212366
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activity of silymarin against chikungunya virus.
Lani R; Hassandarvish P; Chiam CW; Moghaddam E; Chu JJ; Rausalu K; Merits A; Higgs S; Vanlandingham D; Abu Bakar S; Zandi K
Sci Rep; 2015 Jun; 5():11421. PubMed ID: 26078201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
